Search clinical trials for: BI 655064 medium dose

Total 578 results

Boehringer Ingelheim

Completed

Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration

Diabetes Mellitus, Type 1

Canada
University of Utah

Completed

Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose

Venous Thromboembolism | Deep Venous Thrombosis | Pulmonary Embolus

United States
Lundbeck LLC

Completed

Clobazam in Patients With Lennox-Gastaut Syndrome

Epilepsy | Epilepsy, Generalized | Seizures

United States, Belarus, India, Australia, Lithuania
Boehringer Ingelheim

Completed

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Healthy

Germany
Lykos Therapeutics

Completed

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

Posttraumatic Stress Disorder

United States
BioInvent International AB

Terminated

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
Taipei Medical University WanFang Hospital

Unknown

Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea

Type 2 Diabetes

Taiwan
Alan Barkun
Pendopharm

Completed

The Bowel CLEAnsing: A National Initiative (B-CLEAN)

Subjets Requiring a Colonoscopy

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Obesity | Diabetes Mellitus, Type 2

United States, Belgium, Bulgaria, Colombia, Czech Republic, Finland, France, Germany, Guatemala, Mexico, Peru, Russian Federation, Spain, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Diabetes Mellitus, Type 2 | Renal Insufficiency

United States, Canada, France, Hong Kong, India, Malaysia, Netherlands, Philippines, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
Helixmith Co., Ltd.

Unknown

Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea

Ischemic Heart Disease | Acute Myocardial Infarction

Korea, Republic of
Assistance Publique - Hôpitaux de Paris

Recruiting

Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (OPTI-TREX)

Pediatric Kidney Transplant Recipients

France
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function

Hepatic Insufficiency | Healthy

Romania
Maastricht University Medical Center

Completed

Relationship Between Contrast Media Volume and Tube Voltage in CT for Optimal Liver Enhancement, Based on Body Weight. (COMpLEx)

Body Weight | Contrast Media | Radiation | Liver

Netherlands
Tiedra Farmacéutica SL
Hospital Universitario Principe de Asturias

Unknown

Efficacy and Tolerance of Hypertonic Sodium Chloride (NaCl 5%) Eye Drops Without Preservatives in Corneal Edema

Corneal Edema

Spain
Boehringer Ingelheim
Eli Lilly and Company

Completed

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
VA Office of Research and Development

Recruiting

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers (VA-BAT)

Metastatic Prostate Cancer

United States
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

Heart Failure
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Liver Diseases | Hypertension, Portal

Spain, Denmark, Singapore, Germany, Italy, Austria, Canada, Netherlands, China, Israel, Belgium, United States, Japan, Argentina, France, Romania
Boehringer Ingelheim
Eli Lilly and Company

Completed

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Hypertension | Diabetes Mellitus, Type 2

United States, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Lebanon, Netherlands, Norway, Sweden
Boehringer Ingelheim

Completed

Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers

Healthy
Inje University

Unknown

Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy (SP2HP)

Colonoscopy

Korea, Republic of
Sylentis, S.A.

Completed

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Dry Eye Disease | Sjögren Syndrome

United States, Spain
Sinovac Biotech Co., Ltd

Completed

Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization

Poliomyelitis

China
MorphoSys AG
Clinigen Healthcare Ltd

Approved for marketing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

DLBCL
Mario Negri Institute for Pharmacological Research
Ministry of Health, Italy; Azienda Ospedaliera San Gerardo di Monza

Active, not recruiting

Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (STANDLOW)

Epilepsies, Partial

Italy
Boehringer Ingelheim

Completed

Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Argentina, Croatia, Estonia, Germany, Italy, Korea, Republic of, Lithuania, Romania, Russian Federation, Slovakia, Sweden, Taiwan, Ukraine
Sylentis, S.A.

Completed

Safety Study of Tivanisiran to Treat Dry Eye (FYDES)

Dry Eye Disease

United States
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

COVID-19

China
Simon Fraser University
University of British Columbia

Not yet recruiting

NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI (NO AD)

Spinal Cord Injuries | Autonomic Dysreflexia
Tris Pharma, Inc.
Forest Laboratories

Completed

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

Low Back Pain

Austria, Belgium, Denmark, Finland, Germany, Hungary, Netherlands, Poland, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers

Healthy
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

Influenza

China
Boehringer Ingelheim

Completed

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2

Belgium, Canada, France, India, Italy, Korea, Republic of, Malaysia, Netherlands, Spain
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
Xuanwu Hospital, Beijing

Completed

Safety and Efficacy of Low-dose hEparinization in Cerebral Angiography sTudy (SELECT)

Cerebral Angiography | Heparinization

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Diabetes Mellitus, Type 2

United States, Canada, Greece, India, Philippines, Thailand, Ukraine
Boehringer Ingelheim

Completed

BI 10773 Administered as Oral Solution to Healthy Male Volunteers

Healthy
Larissa University Hospital

Terminated

Dopamine in Acute Decompensated Heart Failure II (DAD-HF II)

Acute Decompensated Heart Failure

United States, Greece
SK Bioscience Co., Ltd.
Coalition for Epidemic Preparedness Innovations

Completed

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
Boehringer Ingelheim

Completed

Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis

Knee Osteoarthritis

China

3

Subscribe